查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1933275

全球再生醫學市場：市場規模、佔有率、成長率、產業分析、依類型、應用和地區劃分的考量因素以及未來預測（2026-2034）

Regenerative Medicine Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 192 Pages | 商品交期: 請詢問到貨日

價格

再生醫學市場成長因素

受細胞療法、基因療法、組織工程和富血小板血漿（PRP）療法等創新技術的推動，全球再生醫學市場預計將快速成長。再生醫學專注於利用細胞、組織或遺傳物質來修復、替換或再生受損的組織和器官。 它為包括癌症、帕金森氏症、阿茲海默症、糖尿病、心血管疾病和腎臟病在內的慢性病和末期疾病提供了潛在的治療方案。

根據 Fortune Business Insights 預測，該市場規模預計將在 2025 年達到 516.5 億美元，2026 年增長至 630 億美元，到 2034 年將達到 5555.8 億美元。這意味著從 2026 年到 2034 年，其複合年增長率將高達 31.27%。北美將在 2025 年以 45.38% 的市佔率引領市場，這主要得益於技術進步、細胞和基因療法的快速普及以及有利的監管環境。預計美國市場將經歷顯著成長，到 2032 年將達到 1,842.1 億美元，這主要得益於政府主導的研發計畫和創新產品的批准。 市場驅動因素 研發投入增加和創新產品上市：各國政府、私人企業和學術機構都在大力投資再生醫學，以開發新型療法。例如，2022年7月，華盛頓大學獲得美國國家心肺血液研究所 (NHLBI) 55.7萬美元的撥款，用於推進ETRIM72蛋白的研究。該蛋白旨在再生糖尿病嚴重肢體缺血患者的血管和骨骼肌。同樣，2022年3月，Wipro和Pandorum Technologies合作，將人工智慧融入再生醫學的研發，以加速產品上市速度並改善患者預後。 新興研發管線和臨床候選藥物：製藥和生命科學公司正在拓展再生醫學的應用領域，從傷口護理和組織修復擴展到心臟病學、腫瘤學、神經病學和罕見疾病領域。 2023年11月，希森美康公司（Sysmex Corporation）與JUNTEN BIO簽署了一項免疫耐受療法的授權協議。 2022年6月，CRISPR Therapeutics公司公佈了其針對實體瘤的同種異體CAR-T細胞療法CTX130的I期臨床試驗的正面結果。這些進展將促進產品的廣泛應用，並加速市場成長。

慢性疾病的上升趨勢：糖尿病、癌症、心血管疾病和骨科疾病發生率的上升正在推動對先進再生醫學的需求。特別是，由於其在促進肌肉骨骼疾病癒合和減輕疼痛方面的有效性，預計到2026年，骨科領域將佔40.61%的市場佔有率。

市場限制因子

治療費用高昂且保險覆蓋範圍有限：高昂的費用限制了乾細胞療法（5,000-50,000 美元）和基因療法（如 Zolgensma，212 萬美元）等治療手段的普及。保險覆蓋不足迫使患者自費或依賴眾籌，阻礙了這些療法的廣泛應用。此外，缺乏針對罕見遺傳疾病的核准療法也是市場成長的一大障礙。

市場區隔

依產品分類：

  • 細胞療法：到 2026 年，細胞療法將佔市場主導地位，市佔率達 54.87%，廣泛應用於自體免疫疾病、癌症、傳染病和肌肉骨骼損傷的治療。
  • 基因療法：為脊髓性肌肉萎縮症等罕見疾病提供標靶有效的治療方案。 該細分市場複合年增長率最高。
  • 組織工程：此細分市場佔第二大市場佔有率，主要利用支架、生物基質和皮膚類似物進行傷口護理。
  • 富血小板血漿 (PRP)：此細分市場市佔率最小，但其在骨科和美容領域的應用正在不斷擴展。

依應用領域劃分：

  • 骨科：預計到 2026 年，由於骨骼和關節損傷病例的增加，該細分市場將成為最大的細分市場。
  • 腫瘤科：預計隨著 CAR-T 療法滿足癌症治療領域未被滿足的需求，該細分市場將以較高的複合年增長率成長。
  • 傷口護理：由用於治療慢性傷口的先進生物工程產品推動。
  • 罕見疾病：由於治療選擇有限且患者群體不斷增長，該細分市場是成長最快的。

依最終使用者劃分：

  • 醫院：在外科手術和政府支持的推動下，到 2026 年將佔主導地位，市佔率高達 62.54%。
  • 診所：提供專業的再生醫學服務，將佔第二大市場。
  • 其他：包括學術研究機構，但由於資格限制，其貢獻有限。

區域概覽

北美：2025 年市場規模為 234.4 億美元，預計到 2026 年將達到 270.6 億美元，這主要得益於再生醫學技術 (RMAT) 的審批、技術應用以及強大的研發基礎設施。

歐洲：第二大市場，受惠於政府資助和監管批准。 預計2026年，英國將達到35.8億美元，德國將達到42億美元。

亞太地區：這是成長最快的地區，預計到2026年，日本將達到35.5億美元，中國將達到32.1億美元，印度將達到20.1億美元。成長的驅動因素包括慢性病的普遍流行、政府措施以及可支配收入的增加。

拉丁美洲、中東和非洲：由於醫療保健支出較低以及對治療方法的了解有限，成長速度較慢。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：關鍵考慮因素

  • 全球再生醫學公司：融資狀況
  • 主要國家和地區慢性病盛行率（2025 年）
  • 主要公司研發管線分析
  • 主要公司新產品發布
  • 關鍵產業趨勢：併購、業務合作等
  • 再生醫學技術進步醫學
  • 新冠疫情對全球市場的影響

第五章 全球再生醫學市場分析：洞察與預測（2021-2034）

  • 市場分析、洞察與預測：依產品分類
    • 細胞療法
    • 基因療法
    • 組織工程
    • 富血小板血漿
  • 市場分析、洞察與預測：依應用分類
    • 骨科
    • 傷口護理
    • 腫瘤科
    • 罕見疾病
    • 其他
  • 市場分析、洞察與預測：依最終用戶分類
    • 醫院
    • 臨床醫師
    • 其他
  • 市場分析、洞察與預測：依區域
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章 北美再生醫學市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 美國
    • 加拿大

第七章 歐洲再生醫學市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 斯堪的納維亞
    • 歐洲其他地區

第八章 亞太地區再生醫學市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 東南亞
    • 亞太其他地區

第九章：拉丁美洲再生醫學市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區

第十章：中東與非洲再生醫學市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 海灣合作委員會（GCC）國家/地區
    • 南非
    • 中東和非洲其他地區

第十一章 競爭分析

  • 全球市佔率分析（2025 年）
  • 公司簡介
    • Integra LifeSciences Corporation
    • Bristol-Myers Squibb Company
    • Tissue Regenix
    • Smith &Nephew
    • MiMedx
    • Novartis AG
    • Allergan Aesthetics(AbbVie Inc.)
    • Stryker
    • American CryoStem Corporation
    • Kite(Gilead Sciences, Inc.)
    • AlloSource
    • bluebird bio, Inc.
    • CRISPR Therapeutics
    • Janssen Global Services, LLC(Johnson &Johnson Services, Inc.)
    • Tegoscience
Product Code: FBI100970

Growth Factors of regenerative medicine Market

The global regenerative medicine market is poised for exponential growth, driven by innovations in cell therapy, gene therapy, tissue engineering, and platelet-rich plasma (PRP) therapies. Regenerative medicine focuses on repairing, replacing, or regenerating damaged tissues or organs using cells, tissues, or genetic material. It provides potential treatments for chronic and terminal conditions such as cancers, Parkinson's disease, Alzheimer's disease, diabetes, cardiovascular disorders, and renal diseases.

According to Fortune Business Insights, the market was valued at USD 51.65 billion in 2025, expected to grow to USD 63 billion in 2026, and projected to reach USD 555.58 billion by 2034, reflecting a remarkable CAGR of 31.27% from 2026 to 2034. North America dominated the market in 2025 with a 45.38% share, fueled by technological advancements, rapid adoption of cell and gene therapies, and a supportive regulatory environment. The U.S. market is projected to grow substantially, reaching USD 184.21 billion by 2032, driven by government-backed R&D initiatives and innovative product approvals.

Market Drivers

Increasing R&D Investments and Innovative Product Launches: Governments, private players, and academic institutions are heavily investing in regenerative medicine to develop novel therapies. For instance, in July 2022, Washington University received a grant of USD 557,000 from the NHLBI to study ETRIM72 protein for regenerating vasculature and skeletal muscles in diabetic critical limb ischemia. Similarly, Wipro and Pandorum Technologies partnered in March 2022 to integrate artificial intelligence in regenerative medicine R&D, accelerating time-to-market and improving patient outcomes.

Emerging Pipeline and Clinical Candidates: Pharmaceutical and life sciences companies are broadening applications from wound care and tissue repair to cardiology, oncology, neurology, and rare diseases. In November 2023, Sysmex Corporation entered a licensing agreement with JUNTEN BIO for immune tolerance therapies, and in June 2022, CRISPR Therapeutics reported positive Phase 1 results for its allogeneic CAR-T cell therapy CTX130 targeting solid tumors. Such developments expand product adoption and accelerate market growth.

Rising Prevalence of Chronic Diseases: Increasing incidence of diabetes, cancer, cardiovascular diseases, and orthopedic conditions is creating strong demand for advanced regenerative therapies. The orthopedics segment alone is projected to hold 40.61% of the market share in 2026, as products accelerate healing and reduce pain from musculoskeletal disorders.

Market Restraints

High Treatment Costs and Limited Reimbursement: The high cost of therapies, such as stem cell treatments ranging from USD 5,000-50,000 and gene therapy like Zolgensma at USD 2.12 million, limits accessibility. Inadequate insurance coverage often forces patients to pay out-of-pocket or rely on crowdfunding, hindering adoption. Additionally, limited approved therapies for rare genetic disorders pose barriers to growth.

Market Segmentation

By Product:

  • Cell Therapy: Dominates the market with 54.87% share in 2026, widely used for autoimmune disorders, cancers, infectious diseases, and musculoskeletal injuries.
  • Gene Therapy: Highest CAGR, treating rare diseases such as Spinal Muscular Atrophy, offering targeted, effective interventions.
  • Tissue Engineering: Second-largest share, catering to wound care with scaffolds, biomatrices, and skin-like products.
  • Platelet-Rich Plasma (PRP): Smallest share but growing in orthopedics and cosmetic applications.

By Application:

  • Orthopedics: Largest segment in 2026 due to increasing bone and joint injuries.
  • Oncology: High CAGR as CAR-T therapies meet unmet needs for cancer treatment.
  • Wound Care: Benefiting from advanced bioengineered products for chronic wounds.
  • Rare Diseases: Fastest-growing segment due to limited treatment options and increasing patient population.

By End User:

  • Hospitals: Dominant with 62.54% share in 2026, driven by surgical procedures and government support.
  • Clinics: Second-largest, offering specialized regenerative medicine services.
  • Others: Include academic and research institutes, contributing moderately due to eligibility constraints.

Regional Insights

North America: Valued at USD 23.44 billion in 2025, projected to reach USD 27.06 billion by 2026, driven by RMAT approvals, technological adoption, and strong R&D infrastructure.

Europe: Second-largest market, supported by government funding and regulatory approvals. UK projected at USD 3.58 billion, Germany at USD 4.2 billion by 2026.

Asia Pacific: Fastest-growing, with Japan at USD 3.55 billion, China at USD 3.21 billion, and India at USD 2.01 billion by 2026, fueled by chronic disease prevalence, government initiatives, and rising disposable incomes.

Latin America & MEA: Slower growth due to low healthcare expenditure and limited awareness of therapies.

Competitive Landscape

Key players include Novartis AG, Zimmer Biomet, Gilead Sciences, Stryker, Integra LifeSciences, Kite (Gilead), CRISPR Therapeutics, bluebird bio, and Allergan (AbbVie). Companies are focusing on strategic acquisitions, R&D collaborations, and licensing agreements to strengthen product pipelines and expand global presence.

Recent Developments:

  • February 2024: Iovance Biotherapeutics received FDA approval for TIL therapy (AMTAGVI) for melanoma.
  • September 2023: Launch of Lynch Regenerative Medicine for advanced wound care.
  • February 2023: CSL Behring and UniQure's Hemgenix approved in Europe for hemophilia B treatment.

Conclusion

The global regenerative medicine market is set to expand from USD 51.65 billion in 2025 to USD 63 billion in 2026, reaching an impressive USD 555.58 billion by 2034 at a CAGR of 31.27%. Growth is driven by R&D investments, innovative therapies, rising chronic disease prevalence, and government support. While high costs and limited reimbursement may restrain adoption, technological advancements, regulatory approvals, and strategic collaborations position the market for transformative impact in healthcare globally.

Segmentation By Product

  • Cell Therapy
  • Gene Therapy
  • Tissue Engineering
  • Platelet Rich Plasma

By Application

  • Orthopedics
  • Wound Care
  • Oncology
  • Rare Diseases
  • Others

By End User

  • Hospitals
  • Clinics
  • Others

By Region

  • North America (By Product, By Application, By End User, By Country)
    • U.S.
    • Canada
  • Europe (By Product, By Application, By End User, By Country/Sub-Region)
    • U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Product, By Application, By End User, By Country/Sub-Region)
    • Japan
    • China
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Product, By Application, By End User, By Country/Sub-Region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Product, By Application, By End User, By Country/Sub-Region)
    • GCC
    • South Africa
  • Rest of Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Global Financing of Companies Active in Regenerative Medicine
  • 4.2. Prevalence of Chronic Diseases, By Key Countries/Regions, 2025
  • 4.3. Pipeline Analysis, By Key Players
  • 4.4. New Product Launches, Key Players
  • 4.5. Key Industry Developments: Mergers, Acquisitions & Partnerships
  • 4.6. Technological Developments in Regenerative Medicine
  • 4.7. Impact of COVID-19 on the Global Market

5. Global Regenerative Medicine Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Product
    • 5.1.1. Cell Therapy
    • 5.1.2. Gene Therapy
    • 5.1.3. Tissue Engineering
    • 5.1.4. Platelet Rich Plasma
  • 5.2. Market Analysis, Insights and Forecast - By Application
    • 5.2.1. Orthopedics
    • 5.2.2. Wound Care
    • 5.2.3. Oncology
    • 5.2.4. Rare Diseases
    • 5.2.5. Others
  • 5.3. Market Analysis, Insights and Forecast - By End User
    • 5.3.1. Hospitals
    • 5.3.2. Clinics
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Regenerative Medicine Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Product
    • 6.1.1. Cell Therapy
    • 6.1.2. Gene Therapy
    • 6.1.3. Tissue Engineering
    • 6.1.4. Platelet Rich Plasma
  • 6.2. Market Analysis, Insights and Forecast - By Application
    • 6.2.1. Orthopedics
    • 6.2.2. Wound Care
    • 6.2.3. Oncology
    • 6.2.4. Rare Diseases
    • 6.2.5. Others
  • 6.3. Market Analysis, Insights and Forecast - By End User
    • 6.3.1. Hospitals
    • 6.3.2. Clinics
    • 6.3.3. Others
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Regenerative Medicine Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Product
    • 7.1.1. Cell Therapy
    • 7.1.2. Gene Therapy
    • 7.1.3. Tissue Engineering
    • 7.1.4. Platelet Rich Plasma
  • 7.2. Market Analysis, Insights and Forecast - By Application
    • 7.2.1. Orthopedics
    • 7.2.2. Wound Care
    • 7.2.3. Oncology
    • 7.2.4. Rare Diseases
    • 7.2.5. Others
  • 7.3. Market Analysis, Insights and Forecast - By End User
    • 7.3.1. Hospitals
    • 7.3.2. Clinics
    • 7.3.3. Others
  • 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Spain
    • 7.4.5. Italy
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Regenerative Medicine Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Product
    • 8.1.1. Cell Therapy
    • 8.1.2. Gene Therapy
    • 8.1.3. Tissue Engineering
    • 8.1.4. Platelet Rich Plasma
  • 8.2. Market Analysis, Insights and Forecast - By Application
    • 8.2.1. Orthopedics
    • 8.2.2. Wound Care
    • 8.2.3. Oncology
    • 8.2.4. Rare Diseases
    • 8.2.5. Others
  • 8.3. Market Analysis, Insights and Forecast - By End User
    • 8.3.1. Hospitals
    • 8.3.2. Clinics
    • 8.3.3. Others
  • 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Latin America Regenerative Medicine Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Product
    • 9.1.1. Cell Therapy
    • 9.1.2. Gene Therapy
    • 9.1.3. Tissue Engineering
    • 9.1.4. Platelet Rich Plasma
  • 9.2. Market Analysis, Insights and Forecast - By Application
    • 9.2.1. Orthopedics
    • 9.2.2. Wound Care
    • 9.2.3. Oncology
    • 9.2.4. Rare Diseases
    • 9.2.5. Others
  • 9.3. Market Analysis, Insights and Forecast - By End User
    • 9.3.1. Hospitals
    • 9.3.2. Clinics
    • 9.3.3. Others
  • 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America

10. Middle East & Africa Regenerative Medicine Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Product
    • 10.1.1. Cell Therapy
    • 10.1.2. Gene Therapy
    • 10.1.3. Tissue Engineering
    • 10.1.4. Platelet Rich Plasma
  • 10.2. Market Analysis, Insights and Forecast - By Application
    • 10.2.1. Orthopedics
    • 10.2.2. Wound Care
    • 10.2.3. Oncology
    • 10.2.4. Rare Diseases
    • 10.2.5. Others
  • 10.3. Market Analysis, Insights and Forecast - By End User
    • 10.3.1. Hospitals
    • 10.3.2. Clinics
    • 10.3.3. Others
  • 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.4.1. GCC
    • 10.4.2. South Africa
    • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Integra LifeSciences Corporation
      • 11.2.1.1. Overview
      • 11.2.1.2. Products & Services
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Bristol-Myers Squibb Company
      • 11.2.2.1. Overview
      • 11.2.2.2. Products & Services
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Tissue Regenix
      • 11.2.3.1. Overview
      • 11.2.3.2. Products & Services
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Smith & Nephew
      • 11.2.4.1. Overview
      • 11.2.4.2. Products & Services
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. MiMedx
      • 11.2.5.1. Overview
      • 11.2.5.2. Products & Services
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Novartis AG
      • 11.2.6.1. Overview
      • 11.2.6.2. Products & Services
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Allergan Aesthetics (AbbVie Inc.)
      • 11.2.7.1. Overview
      • 11.2.7.2. Products & Services
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Stryker
      • 11.2.8.1. Overview
      • 11.2.8.2. Products & Services
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. American CryoStem Corporation
      • 11.2.9.1. Overview
      • 11.2.9.2. Products & Services
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)
    • 11.2.10. Kite (Gilead Sciences, Inc.)
      • 11.2.10.1. Overview
      • 11.2.10.2. Products & Services
      • 11.2.10.3. SWOT Analysis
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. Financials (Based on Availability)
    • 11.2.11. AlloSource
      • 11.2.11.1. Overview
      • 11.2.11.2. Products & Services
      • 11.2.11.3. SWOT Analysis
      • 11.2.11.4. Recent Developments
      • 11.2.11.5. Strategies
      • 11.2.11.6. Financials (Based on Availability)
    • 11.2.12. bluebird bio, Inc.
      • 11.2.12.1. Overview
      • 11.2.12.2. Products & Services
      • 11.2.12.3. SWOT Analysis
      • 11.2.12.4. Recent Developments
      • 11.2.12.5. Strategies
      • 11.2.12.6. Financials (Based on Availability)
    • 11.2.13. CRISPR Therapeutics
      • 11.2.13.1. Overview
      • 11.2.13.2. Products & Services
      • 11.2.13.3. SWOT Analysis
      • 11.2.13.4. Recent Developments
      • 11.2.13.5. Strategies
      • 11.2.13.6. Financials (Based on Availability)
    • 11.2.14. Janssen Global Services, LLC (Johnson & Johnson Services, Inc.)
      • 11.2.14.1. Overview
      • 11.2.14.2. Products & Services
      • 11.2.14.3. SWOT Analysis
      • 11.2.14.4. Recent Developments
      • 11.2.14.5. Strategies
      • 11.2.14.6. Financials (Based on Availability)
    • 11.2.15. Tegoscience
      • 11.2.15.1. Overview
      • 11.2.15.2. Products & Services
      • 11.2.15.3. SWOT Analysis
      • 11.2.15.4. Recent Developments
      • 11.2.15.5. Strategies
      • 11.2.15.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Regenerative Medicine Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 2: Global Regenerative Medicine Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 3: Global Regenerative Medicine Market Revenue (USD billion) Forecast, By End User, 2021-2034
  • Table 4: Global Regenerative Medicine Market Revenue (USD billion) Forecast, By Region, 2021-2034
  • Table 5: North America Regenerative Medicine Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 6: North America Regenerative Medicine Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 7: North America Regenerative Medicine Market Revenue (USD billion) Forecast, By End User, 2021-2034
  • Table 8: North America Regenerative Medicine Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 9: Europe Regenerative Medicine Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 10: Europe Regenerative Medicine Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 11: Europe Regenerative Medicine Market Revenue (USD billion) Forecast, By End User, 2021-2034
  • Table 12: Europe Regenerative Medicine Market Revenue (USD billion) Forecast, By Country/ Sub-Region, 2021-2034
  • Table 13: Asia Pacific Regenerative Medicine Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 14: Asia Pacific Regenerative Medicine Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 15: Asia Pacific Regenerative Medicine Market Revenue (USD billion) Forecast, By End User, 2021-2034
  • Table 16: Asia Pacific Regenerative Medicine Market Revenue (USD billion) Forecast, By Country/ Sub-Region, 2021-2034
  • Table 17: Latin America Regenerative Medicine Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 18: Latin America Regenerative Medicine Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 19: Latin America Regenerative Medicine Market Revenue (USD billion) Forecast, By End User, 2021-2034
  • Table 20: Latin America Regenerative Medicine Market Revenue (USD billion) Forecast, By Country/ Sub-Region, 2021-2034
  • Table 21: Middle East & Africa Regenerative Medicine Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 22: Middle East & Africa Regenerative Medicine Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 23: Middle East & Africa Regenerative Medicine Market Revenue (USD billion) Forecast, By End User, 2021-2034
  • Table 24: Middle East & Africa Regenerative Medicine Market Revenue (USD billion) Forecast, By Country/ Sub-Region, 2021-2034

List of Figures

  • Figure 1: Global Regenerative Medicine Market Value Share (%), By Product, 2025 & 2034
  • Figure 2: Global Regenerative Medicine Market Value Share (%), By Application, 2025 & 2034
  • Figure 3: Global Regenerative Medicine Market Value Share (%), By End User, 2025 & 2034
  • Figure 4: Global Regenerative Medicine Market Value (USD billion), By Region, 2025 & 2034
  • Figure 5: North America Regenerative Medicine Market Value (USD billion), by Product, 2025 & 2034
  • Figure 6: North America Regenerative Medicine Market Value Share (%), by Product, 2025
  • Figure 7: North America Regenerative Medicine Market Value (USD billion), by Application, 2025 & 2034
  • Figure 8: North America Regenerative Medicine Market Value Share (%), by Application, 2025
  • Figure 9: North America Regenerative Medicine Market Value (USD billion), by End User, 2025 & 2034
  • Figure 10: North America Regenerative Medicine Market Value Share (%), by End User, 2025
  • Figure 11: North America Regenerative Medicine Market Value (USD billion), by Country, 2025 & 2034
  • Figure 12: North America Regenerative Medicine Market Value Share (%), by Country, 2025
  • Figure 13: Europe Regenerative Medicine Market Value (USD billion), by Product, 2025 & 2034
  • Figure 14: Europe Regenerative Medicine Market Value Share (%), by Product, 2025
  • Figure 15: Europe Regenerative Medicine Market Value (USD billion), by Application, 2025 & 2034
  • Figure 16: Europe Regenerative Medicine Market Value Share (%), by Application, 2025
  • Figure 17: Europe Regenerative Medicine Market Value (USD billion), by End User, 2025 & 2034
  • Figure 18: Europe Regenerative Medicine Market Value Share (%), by End User, 2025
  • Figure 19: Europe Regenerative Medicine Market Value (USD billion), by Country/ Sub-Region, 2025 & 2034
  • Figure 20: Europe Regenerative Medicine Market Value Share (%), by Country/ Sub-Region, 2025
  • Figure 21: Asia Pacific Regenerative Medicine Market Value (USD billion), by Product, 2025 & 2034
  • Figure 22: Asia Pacific Regenerative Medicine Market Value Share (%), by Product, 2025
  • Figure 23: Asia Pacific Regenerative Medicine Market Value (USD billion), by Application, 2025 & 2034
  • Figure 24: Asia Pacific Regenerative Medicine Market Value Share (%), by Application, 2025
  • Figure 25: Asia Pacific Regenerative Medicine Market Value (USD billion), by End User, 2025 & 2034
  • Figure 26: Asia Pacific Regenerative Medicine Market Value Share (%), by End User, 2025
  • Figure 27: Asia Pacific Regenerative Medicine Market Value (USD billion), by Country/ Sub-Region, 2025 & 2034
  • Figure 28: Asia Pacific Regenerative Medicine Market Value Share (%), by Country/ Sub-Region, 2025
  • Figure 29: Latin America Regenerative Medicine Market Value (USD billion), by Product, 2025 & 2034
  • Figure 30: Latin America Regenerative Medicine Market Value Share (%), by Product, 2025
  • Figure 31: Latin America Regenerative Medicine Market Value (USD billion), by Application, 2025 & 2034
  • Figure 32: Latin America Regenerative Medicine Market Value Share (%), by Application, 2025
  • Figure 33: Latin America Regenerative Medicine Market Value (USD billion), by End User, 2025 & 2034
  • Figure 34: Latin America Regenerative Medicine Market Value Share (%), by End User, 2025
  • Figure 35: Latin America Regenerative Medicine Market Value (USD billion), by Country/ Sub-Region, 2025 & 2034
  • Figure 36: Latin America Regenerative Medicine Market Value Share (%), by Country/ Sub-Region, 2025
  • Figure 37: Middle East & Africa Regenerative Medicine Market Value (USD billion), by Product, 2025 & 2034
  • Figure 38: Middle East & Africa Regenerative Medicine Market Value Share (%), by Product, 2025
  • Figure 39: Middle East & Africa Regenerative Medicine Market Value (USD billion), by Application, 2025 & 2034
  • Figure 40: Middle East & Africa Regenerative Medicine Market Value Share (%), by Application, 2025
  • Figure 41: Middle East & Africa Regenerative Medicine Market Value (USD billion), by End User, 2025 & 2034
  • Figure 42: Middle East & Africa Regenerative Medicine Market Value Share (%), by End User, 2025
  • Figure 43: Middle East & Africa Regenerative Medicine Market Value (USD billion), by Country/ Sub-Region, 2025 & 2034
  • Figure 44: Middle East & Africa Regenerative Medicine Market Value Share (%), by Country/ Sub-Region, 2025
  • Figure 45: Global Regenerative Medicine Market Share (%), By Company, 2025